BTK and B-cell chronic lymphocytic leukemia: Other studies corroborate this low seroconversion rates for CLL patients, estimated at 18% following a single dose [43] and that is most likely influenced by the severe B cell impairment in CLL patients treated with B cell depleting or targeted therapies such as anti-CD20 or BTK inhibitors [39,44].